Photo od Ahmed Kotb
from daiichisankyo.us
Jun 22, 2025, 11:29
Ahmed Kotb: Choosing the Right DOAC For Your Patient?
Ahmed Kotb, Head of Global Oncology Medical Affairs at Daiichi Sankyo, shared on X:
“Choosing the right DOAC for your patient?
anticoagulant choice based on clinical profiles”
Elderly/Frail- Apixaban, Edoxaban
Obese -Apixaban or Rivaroxaban
CKD Apixaban, Edoxaban 30mg
GI Bleed Risk-Apixaban
Compliance issues- Edoxaban, Rivaroxaban
You can explore more detailed, evidence-based insights on individualized anticoagulant therapy at Hemostasis Today, your source for expert-guided approaches in thrombosis and hemostasis.
-
Jan 10, 2026, 08:56Shivanand Kumatagi Reflects on His Visit to Rela Hospital
-
Jan 10, 2026, 08:48Mitchell Elkind: Why Is The American Heart Association Holding a Brain Health Symposium?
-
Jan 10, 2026, 08:41Fiona Robinson Invites You to NBDF Webinar on Research Grants
-
Jan 10, 2026, 08:30Melissa Korn Takes Front Page Award for Her WSJ Piece on Experiencing a Pulmonary Embolism
-
Jan 10, 2026, 08:20Aymar Akilimali on Malaria in the Democratic Republic of Congo
-
Jan 9, 2026, 12:17Louise St Germain Bannon Invites You to Self-Nominate for the ISTH Council
-
Jan 9, 2026, 09:25Emma Groarke Shares A Comprehensive Review on VEXAS Syndrome
-
Jan 9, 2026, 09:13Anirban Sen Gupta Presents PlateChek
-
Jan 9, 2026, 08:58Oscar Pena Shares KDIGO 2026 Update: 5 Critical Changes for Anemia in CKD Management